Vixarelimab for Pulmonary Fibrosis
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Verified Trial
Recruiting
Sponsor: Genentech, Inc.
Prior Safety Data
Trial Summary
What is the purpose of this trial?This trial is testing vixarelimab, a medication that may help improve lung function, in people with IPF and SSc-ILD. It works by reducing inflammation and scarring in the lungs to help with breathing.
What data supports the idea that Vixarelimab for Pulmonary Fibrosis is an effective drug?The available research does not provide any data on Vixarelimab for Pulmonary Fibrosis. Instead, the studies focus on treatments for rheumatoid arthritis and related conditions, with no mention of Vixarelimab or its effectiveness for Pulmonary Fibrosis. Therefore, there is no data here to support the idea that Vixarelimab is an effective drug for Pulmonary Fibrosis.46111213
Do I have to stop taking my current medications for the trial?The trial does not specify that you must stop taking your current medications. If you are taking pirfenidone or nintedanib for IPF, or tocilizumab or nintedanib for SSc-ILD, you should continue these treatments with a stable dose during the study.
Is the drug Vixarelimab a promising treatment for Pulmonary Fibrosis?The information provided does not mention Vixarelimab or its effects on Pulmonary Fibrosis, so we cannot determine if it is a promising treatment based on the given data.1591014
What safety data is available for Vixarelimab in treating pulmonary fibrosis?The provided research does not contain any safety data for Vixarelimab or its other names (KPL-716, BIIB069, BIIB-069, RG-6536, RO-7622888) in the context of pulmonary fibrosis. The studies listed focus on other treatments and conditions, such as filgotinib for rheumatoid arthritis, dupilumab for asthma, tocilizumab for rheumatoid arthritis, and adalimumab for rheumatoid arthritis.237813
Eligibility Criteria
Adults aged 18-85 with idiopathic pulmonary fibrosis or systemic sclerosis-associated interstitial lung disease, who have a certain level of lung function and are considering all treatment options including possible lung transplantation. Excluded are those with active infections, significant emphysema, history of lung transplant or malignancy within the past 5 years, among other criteria.Inclusion Criteria
I can walk at least 150 meters with up to 6L/min of oxygen, or 8L/min if I'm at a high altitude, and keep my oxygen level above 83%.
I am between 40 and 85 years old.
I have been diagnosed with IPF or it's likely I have IPF.
My lung scans and any lung biopsies confirm I have idiopathic pulmonary fibrosis.
I have been on a stable dose of pirfenidone or nintedanib for my IPF for at least 4 weeks.
I am between 18 and 85 years old.
I have been diagnosed with systemic sclerosis according to ACR/EULAR criteria.
My lung scarring is getting worse.
I have completed 52 weeks of treatment in a previous study phase.
Exclusion Criteria
My oxygen levels are below 89% even with extra oxygen.
I have had a lung transplant.
I have been treated with vixarelimab before.
I am being treated for high blood pressure in my lungs.
I have had cancer within the last 5 years.
I have active or untreated latent tuberculosis.
More than half of my lung scan shows emphysema, more than fibrosis.
I have an autoimmune disease that is not systemic sclerosis.
I haven't developed any new lung diseases since starting the treatment.
Treatment Details
The trial is testing Vixarelimab's effectiveness on improving lung function compared to a placebo in patients with specific types of lung diseases over a period of one year. Those completing this phase can continue for another year in an open-label extension to receive Vixarelimab.
6Treatment groups
Experimental Treatment
Placebo Group
Group I: OLE Period: Cohort 2: VixarelimabExperimental Treatment1 Intervention
Participants with SSC-ILD who complete 52 weeks of treatment in the DBT period can choose to enroll in the OLE period to receive vixarelimab, SC, Q2W for 52 weeks.
Group II: OLE Period: Cohort 1: VixarelimabExperimental Treatment1 Intervention
Participants with IPF who complete 52 weeks of treatment in the DBT period can choose to enroll in the OLE period to receive vixarelimab, SC, Q2W for 52 weeks.
Group III: DBT: Cohort 2: VixarelimabExperimental Treatment1 Intervention
Participants with SSC-ILD will receive vixarelimab, SC, Q2W for 52 weeks in the DBT period.
Group IV: DBT: Cohort 1: VixarelimabExperimental Treatment1 Intervention
Participants with IPF will receive vixarelimab, subcutaneously (SC), once every two weeks (Q2W) for 52 weeks in the DBT period.
Group V: DBT: Cohort 1: PlaceboPlacebo Group1 Intervention
Participants with IPF will receive vixarelimab matching placebo, SC, Q2W for 52 weeks in the DBT period.
Group VI: DBT: Cohort 2: PlaceboPlacebo Group1 Intervention
Participants with SSC-ILD will receive vixarelimab matching placebo, SC, Q2W for 52 weeks in the DBT period.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Pulmonix LLCGreensboro, NC
Southern Arizona VA Health Care System NAVREF PPDSTucson, AZ
University of California, San Francisco-FresnoFresno, CA
UCLA RheumatologyLos Angeles, CA
More Trial Locations
Loading ...
Who is running the clinical trial?
Genentech, Inc.Lead Sponsor
References
Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. [2019]Treatment options for patients with pulmonary fibrosis associated with rheumatoid disease are limited. We report a case of a 71-year-old man with a 3-year history of seropositive rheumatoid arthritis (RA) referred to the pulmonary clinic because of progressive pulmonary symptoms associated with radiographic fibrosis that was progressive in spite of corticosteroid treatment. In an attempt to control his articular symptoms and alter the course of his pulmonary fibrosis, treatment with IV infusion of the tumor necrosis factor (TNF)-alpha inhibitor infliximab was initiated. Following 1 year of therapy with this agent, the patient reported sustained improvement in dyspnea, cough, and exercise tolerance, in addition to improvement in joint symptoms. Stabilization of pulmonary function was indicated by repeat pulmonary function test findings. This report suggests that inhibition of TNF-alpha may be of significant benefit to patients with fibrosing lung conditions in the setting of RA.
[Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.]. [2018]To investigate the efficacy and safety of adalimumab plus methotrexate (MTX) for the treatment of rheumatoid arthritis (RA).
Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. [2018]to compare the benefit and safety of tocilizumab to placebo in patients with rheumatoid arthritis (RA).
Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. [2022]This 24-week, multicenter, double-blind, randomized, placebo-controlled study (NCT00791999) compared efficacy and safety of certolizumab pegol (CZP) in combination with methotrexate (MTX) vs placebo plus MTX in Japanese rheumatoid arthritis (RA) patients with inadequate response to MTX.
Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. [2022]To evaluate the effect of rituximab (RTX) in patients with RA-related interstitial lung disease (RA-ILD) and identify factors associated with outcome after treatment.
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. [2020]To compare the effectiveness and safety of three non-tumour necrosis factor (TNF) α inhibitors (rituximab, abatacept, and tocilizumab) in the treatment of rheumatoid arthritis.
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. [2022]Label="BACKGROUND" NlmCategory="BACKGROUND">Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab 200 mg or 300 mg every 2 weeks reduced exacerbations and improved forced expiratory volume in 1 s (FEV1) and quality of life over 52 weeks. This analysis evaluates dupilimab's effect on lung function in the overall population, and subgroups with baseline elevated type 2 inflammatory biomarkers.
Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. [2022]Label="BACKGROUND" NlmCategory="BACKGROUND">In the LIBERTY ASTHMA QUEST (ClinicalTrials.gov: NCT02414854) study, dupilumab 200 mg and 300 mg every 2 weeks vs matched-volume placebo reduced severe asthma exacerbations and improved lung function (FEV1), asthma control, and quality of life in patients with uncontrolled, moderate-to-severe asthma (N = 1902). Here, we examine the safety and efficacy of dupilumab in the subpopulation of Japanese patients who participated in QUEST (n = 114; 6%).
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. [2021]This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis (IPF).Patients with IPF aged ≥40 years with forced vital capacity (FVC) of 40%-100% predicted and diffusing capacity for carbon monoxide of 25%-90% predicted and who were treatment-naïve (cohort A) or receiving pirfenidone (2403 mg·day-1; cohort B) were randomised 1:1 to receive lebrikizumab 250 mg or placebo subcutaneously every 4 weeks. The primary endpoint was annualised rate of FVC % predicted decline over 52 weeks.In cohort A, 154 patients were randomised to receive lebrikizumab (n=78) or placebo (n=76). In cohort B, 351 patients receiving pirfenidone were randomised to receive lebrikizumab (n=174) or placebo (n=177). Baseline demographics were balanced across treatment arms in both cohorts. The primary endpoint (annualised rate of FVC % predicted decline) was not met in cohort A (lebrikizumab versus placebo, -5.2% versus -6.2%; p=0.456) or cohort B (lebrikizumab versus placebo, -5.5% versus -6.0%; p=0.557). In cohort B, a non-statistically significant imbalance in mortality favouring combination therapy was observed (hazard ratio 0.42 (95% CI 0.17-1.04)). Pharmacodynamic biomarkers indicated lebrikizumab activity. The safety profile was consistent with that in previous studies of lebrikizumab and pirfenidone as monotherapies.Lebrikizumab alone or with pirfenidone was not associated with reduced FVC % predicted decline over 52 weeks despite evidence of pharmacodynamic activity. Lebrikizumab was well tolerated with a favourable safety profile. These findings suggest that blocking IL-13 may not be sufficient to achieve a lung function benefit in patients with IPF.
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. [2022]Label="BACKGROUND">The INBUILD trial investigated nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs). We investigated the decline in forced vital capacity (FVC) in subgroups based on the inclusion criteria for ILD progression.
Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. [2021]The relative efficacy and tolerability of tocilizumab, sarilumab, and sirukumab as monotherapy were assessed and compared with those of adalimumab in patients with rheumatoid arthritis (RA) who were intolerant to or responded inadequately to methotrexate (MTX).
A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. [2022]To examine the effectiveness of Janus-kinase inhibitors (JAKis) or abatacept (ABA) in patients with rheumatoid arthritis-interstitial lung disease (RA-ILD).
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3). [2023]To evaluate the long-term safety and efficacy of filgotinib (FIL) for Japanese patients with rheumatoid arthritis (RA) and limited/no prior methotrexate (MTX) exposure. We present a Japanese population subanalysis of a global randomised-controlled trial at Week 52 and interim long-term extension (LTE) to Week 48 through June 2020.
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF). [2023]IntroductionThere is an unmet need for new treatments for idiopathic pulmonary fibrosis (IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in forced vital capacity (FVC) in a phase II study in patients with IPF. This study design describes the subsequent pivotal phase III study of BI 1015550 in patients with IPF (FIBRONEER-IPF).